Your browser doesn't support javascript.
loading
The Role of IL-35 in the Pathophysiological Processes of Liver Disease.
Hu, Shuang; Lian, Pan-Pan; Hu, Ying; Zhu, Xing-Yu; Jiang, Shao-Wei; Ma, Qiang; Li, Liang-Yun; Yang, Jun-Fa; Yang, Li; Guo, Hai-Yue; Zhou, Hong; Yang, Chen-Chen; Meng, Xiao-Ming; Li, Jun; Li, Hai-Wen; Xu, Tao; Zhou, Huan.
Afiliação
  • Hu S; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Lian PP; Institute for Liver Diseases of Anhui Medical University, Hefei, China.
  • Hu Y; School of Pharmacy, NanJing University, NanJing, China.
  • Zhu XY; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Jiang SW; Institute for Liver Diseases of Anhui Medical University, Hefei, China.
  • Ma Q; National Drug Clinical Trial Institution, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Li LY; The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Yang JF; Second Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Yang L; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Guo HY; Institute for Liver Diseases of Anhui Medical University, Hefei, China.
  • Zhou H; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Yang CC; Institute for Liver Diseases of Anhui Medical University, Hefei, China.
  • Meng XM; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Li J; Institute for Liver Diseases of Anhui Medical University, Hefei, China.
  • Li HW; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Xu T; Institute for Liver Diseases of Anhui Medical University, Hefei, China.
  • Zhou H; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.
Front Pharmacol ; 11: 569575, 2020.
Article em En | MEDLINE | ID: mdl-33584256
It is known that liver diseases have several characteristics of massive lipid accumulation and lipid metabolic disorder, and are divided into liver inflammation, liver fibrosis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in patients. Interleukin (IL)-35, a new-discovered cytokine, can protect the liver from the environmental attack by increasing the ratio of Tregs (T regulatory cells) which can increase the anti-inflammatory cytokines and inhibit the proliferation of immune cellular. Interestingly, two opposite mechanisms (pro-inflammatory and anti-inflammatory) have connection with the ultimate formation of liver diseases, which suggest that IL-35 may play crucial function in the process of liver diseases through immunosuppressive regulation. Besides, some obvious advantages also imply that IL-35 can be considered as a new therapeutic target to control the progression of liver diseases, while its mechanism of function still needs further research.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Suíça